5d 1m 3m 1y 5y 10y
There is research on this stock available only to PRO subscribers.
There are no News articles on NRIFF.
NRIFF vs. ETF Alternatives
Friday, Jan 177:32 AM
Friday, Jan 177:32 AM| Comment!
- The FDA has approved Mallinckrodt's (MNK) NDA for Pennsaid 2%, a topical non-steroidal anti-inflammatory treatment for osteoarthritis of the knee.
- U.S. sales and marketing rights for Pennsaod are licensed to Mallinckrodt by Nuvo Research (NRIFF).
- The approval comes with warnings about the risks of non-steroidal anti-inflammatories to the heart and the rest of the cardiovascular system, and to the liver. (PR)